$RYTM
RHYTHM PHARMACEUTICALS, INC.
Runway:23 mo
NasdaqMarket cap: —CIK 0001649904
Upcoming catalysts
0 surfacedNo catalysts surfaced for RYTM yet.
Drug pipeline
Recent & active trials
| NCT | Drug | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07156578 | Bivamelagon | Phase 2 | Enrolling By Invitation | 2028-04-15 |
| NCT06239116 | Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) | Phase 2 | Recruiting | 2027-11-01 |
| NCT06596135 | Setmelanotide | Phase 3 | Enrolling By Invitation | 2027-10-30 |
| NCT06760546 | Setmelanotide | Phase 3 | Recruiting | 2027-03-13 |
| NCT06772597 | Setmelanotide | Phase 2 | Active Not Recruiting | 2026-10-31 |
| NCT06046443 | LB54640 | Phase 2 | Completed | 2026-02-09 |
| NCT05093634 | Setmelanotide | Phase 3 | Active Not Recruiting | 2025-12-22 |
| NCT05774756 | Setmelanotide | Phase 3 | Active Not Recruiting | 2025-03-18 |
| NCT03651765 | Setmelanotide | Phase 3 | Completed | 2025-01-09 |
| NCT05194124 | Setmelanotide 2 mg | Phase 3 | Completed | 2023-10-19 |
| NCT04966741 | Setmelanotide | Phase 3 | Completed | 2023-09-18 |
| NCT04963231 | Setmelanotide | Phase 2 | Completed | 2023-08-04 |
| NCT04725240 | Setmelanotide | Phase 2 | Completed | 2022-06-28 |
| NCT05046132 | Setmelanotide | Phase 4 | Completed | 2022-04-07 |
| NCT03013543 | Setmelanotide | Phase 2 | Completed | 2022-03-01 |
| NCT04348175 | Setmelanotide | Phase 1 | Completed | 2021-04-17 |
| NCT03621007 | — | — | Completed | 2021-01-22 |
| NCT03479437 | — | — | Completed | 2020-12-01 |
| NCT03746522 | Setmelanotide | Phase 3 | Completed | 2020-11-16 |
| NCT03287960 | Setmelanotide | Phase 3 | Completed | 2020-09-25 |